Dataset Information

Prevalence of Gastrointestinal Symptoms in Severe Acute Respiratory Syndrome Coronavirus 2 Infection: Results of the Prospective Controlled Multinational GI-COVID-19 Study.

ABSTRACT:

Introduction

Gastrointestinal (GI) symptoms in coronavirus-19 disease (COVID-19) have been reported with great variability and without standardization. In hospitalized patients, we aimed to evaluate the prevalence of GI symptoms, factors associated with their occurrence, and variation at 1 month.

Methods

The GI-COVID-19 is a prospective, multicenter, controlled study. Patients with and without COVID-19 diagnosis were recruited at hospital admission and asked for GI symptoms at admission and after 1 month, using the validated Gastrointestinal Symptom Rating Scale questionnaire.

Results

The study included 2036 hospitalized patients. A total of 871 patients (575 COVID+ and 296 COVID-) were included for the primary analysis. GI symptoms occurred more frequently in patients with COVID-19 (59.7%; 343/575 patients) than in the control group (43.2%; 128/296 patients) (P < 0.001). Patients with COVID-19 complained of higher presence or intensity of nausea, diarrhea, loose stools, and urgency as compared with controls. At a 1-month follow-up, a reduction in the presence or intensity of GI symptoms was found in COVID-19 patients with GI symptoms at hospital admission. Nausea remained increased over controls. Factors significantly associated with nausea persistence in COVID-19 were female sex, high body mass index, the presence of dyspnea, and increased C-reactive protein levels.

Discussion

The prevalence of GI symptoms in hospitalized patients with COVID-19 is higher than previously reported. Systemic and respiratory symptoms are often associated with GI complaints. Nausea may persist after the resolution of COVID-19 infection.

SUBMITTER: Marasco G

PROVIDER: S-EPMC10337314 | biostudies-literature | 2022 Jan

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Prevalence of Gastrointestinal Symptoms in Severe Acute Respiratory Syndrome Coronavirus 2 Infection: Results of the Prospective Controlled Multinational GI-COVID-19 Study.

Marasco Giovanni G Cremon Cesare C Barbaro Maria Raffaella MR Salvi Daniele D Cacciari Giulia G Kagramanova Anna A Bordin Dmitry D Drug Vasile V Miftode Edgidia E Fusaroli Pietro P Mohamed Salem Youssef SY Ricci Chiara C Bellini Massimo M Rahman M Masudur MM Melcarne Luigi L Santos Javier J Lobo Beatriz B Bor Serhat S Yapali Suna S Akyol Deniz D Sapmaz Ferdane Pirincci FP Urun Yonca Yilmaz YY Eskazan Tugce T Celebi Altay A Kacmaz Huseyin H Ebik Berat B Binicier Hatice Cilem HC Bugdayci Mehmet Sait MS Yağcı Munkhtsetseg Banzragch MB Pullukcu Husnu H Kaya Berrin Yalınbas BY Tureyen Ali A Hatemi İbrahim İ Koc Elif Sitre ES Sirin Goktug G Calıskan Ali Riza AR Bengi Goksel G Alıs Esra Ergun EE Lukic Snezana S Trajkovska Meri M Hod Keren K Dumitrascu Dan D Pietrangelo Antonello A Corradini Elena E Simren Magnus M Sjolund Jessica J Tornkvist Navkiran N Ghoshal Uday C UC Kolokolnikova Olga O Colecchia Antonio A Serra Jordi J Maconi Giovanni G De Giorgio Roberto R Danese Silvio S Portincasa Pietro P Di Stefano Michele M Maggio Marcello M Philippou Elena E Lee Yeong Yeh YY Venturi Alessandro A Borghi Claudio C Zoli Marco M Gionchetti Paolo P Viale Pierluigi P Stanghellini Vincenzo V Barbara Giovanni G

The American journal of gastroenterology 20220101 1

<h4>Introduction</h4>Gastrointestinal (GI) symptoms in coronavirus-19 disease (COVID-19) have been reported with great variability and without standardization. In hospitalized patients, we aimed to evaluate the prevalence of GI symptoms, factors associated with their occurrence, and variation at 1 month.<h4>Methods</h4>The GI-COVID-19 is a prospective, multicenter, controlled study. Patients with and without COVID-19 diagnosis were recruited at hospital admission and asked for GI symptoms at adm ...[more]

PMID: 34751672

Similar Datasets

Project description:BackgroundUp to 30% of hospitalised patients with COVID-19 require advanced respiratory support, including high-flow nasal cannulas (HFNC), non-invasive mechanical ventilation (NIV), or invasive mechanical ventilation (IMV). We aimed to describe the clinical characteristics, outcomes and risk factors for failing non-invasive respiratory support in patients treated with severe COVID-19 during the first two years of the pandemic in high-income countries (HICs) and low middle-income countries (LMICs).MethodsThis is a multinational, multicentre, prospective cohort study embedded in the ISARIC-WHO COVID-19 Clinical Characterisation Protocol. Patients with laboratory-confirmed SARS-CoV-2 infection who required hospital admission were recruited prospectively. Patients treated with HFNC, NIV, or IMV within the first 24 h of hospital admission were included in this study. Descriptive statistics, random forest, and logistic regression analyses were used to describe clinical characteristics and compare clinical outcomes among patients treated with the different types of advanced respiratory support.ResultsA total of 66,565 patients were included in this study. Overall, 82.6% of patients were treated in HIC, and 40.6% were admitted to the hospital during the first pandemic wave. During the first 24 h after hospital admission, patients in HICs were more frequently treated with HFNC (48.0%), followed by NIV (38.6%) and IMV (13.4%). In contrast, patients admitted in lower- and middle-income countries (LMICs) were less frequently treated with HFNC (16.1%) and the majority received IMV (59.1%). The failure rate of non-invasive respiratory support (i.e. HFNC or NIV) was 15.5%, of which 71.2% were from HIC and 28.8% from LMIC. The variables most strongly associated with non-invasive ventilation failure, defined as progression to IMV, were high leukocyte counts at hospital admission (OR [95%CI]; 5.86 [4.83-7.10]), treatment in an LMIC (OR [95%CI]; 2.04 [1.97-2.11]), and tachypnoea at hospital admission (OR [95%CI]; 1.16 [1.14-1.18]). Patients who failed HFNC/NIV had a higher 28-day fatality ratio (OR [95%CI]; 1.27 [1.25-1.30]).ConclusionsIn the present international cohort, the most frequently used advanced respiratory support was the HFNC. However, IMV was used more often in LMIC. Higher leucocyte count, tachypnoea, and treatment in LMIC were risk factors for HFNC/NIV failure. HFNC/NIV failure was related to worse clinical outcomes, such as 28-day mortality. Trial registration This is a prospective observational study; therefore, no health care interventions were applied to participants, and trial registration is not applicable.

Dataset Information

Prevalence of Gastrointestinal Symptoms in Severe Acute Respiratory Syndrome Coronavirus 2 Infection: Results of the Prospective Controlled Multinational GI-COVID-19 Study.

Introduction

Methods

Results

Discussion

Publications

Prevalence of Gastrointestinal Symptoms in Severe Acute Respiratory Syndrome Coronavirus 2 Infection: Results of the Prospective Controlled Multinational GI-COVID-19 Study.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets